Ipravacaine (IQB-9302) is a long-acting amide-based local anesthetic. Ipravacaine blocks open-state hKv1.5 , with stereoselective, time-dependent and voltage-dependent inhibitory effects, and exerts stronger activity on the R (+) enantiomer. Ipravacaine blocks Kv2.1 , Kv4.3 and HERG potassium channels. Ipravacaine induces negative chronotropic effects, increases mean arterial pressure, and exhibits vasodilatory effects at high concentrations. Ipravacaine impairs cardiac electrical conduction function, and high-dose intravenous administration can cause cardiac arrest and death. In rats, Ipravacaine shows better intravenous tolerance at a dose of 3 mg/kg.
Products | Products > Disease Areas > Others | Products > Signaling Pathways > Membrane Transporter/Ion Channel | Products > Research Areas > Others | Products > Signaling Pathways > Potassium Channel
Please leave a message for us or use the following ways to contact us, we will reply to you as soon as possible, and provide you with the most sincere service, thank you.
日本语
한국어
Français
Deutsch
España
Türkiye